Open AccessExtended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain
Author(s) -
Jose M. Pacheco,
Dexiang Gao,
D. Ross Camidge
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.05.72
Subject(s) - pembrolizumab , medicine , oncology , lung cancer , chemotherapy , overall survival , cancer , immunotherapy